<DOC>
	<DOCNO>NCT02426112</DOCNO>
	<brief_summary>Chronic pulmonary disease ( CLD ) common manifestation HIV/AIDS among child , account 50 % HIV-associated mortality . Recently , novel form CLD , affect 30 % African HIV-infected older child describe Ferrand et al Zimbabwe , high-resolution CT scanning finding show predominantly small airway disease consistent constrictive obliterative bronchiolitis ( OB ) . . Azithromycin anti-inflammatory activity treatment CLD agent may lead suppression generalize immune activation . This specific aim project : 1 . Primary objective : To investigate whether adjuvant treatment azithromycin result improvement lung function HIV-infected child chronic lung disease , stable antiretroviral therapy . 2 . Secondary objective : 1 . To investigate intervention effect mortality , exacerbation lung disease , quality life , morbidity . 2 . To investigate adverse event related azithromycin treatment In total , 400 child age 6-16 year , live HIV diagnose CLD enrol Harare ChildrenÂ´s Hospital Harare ( Zimbabwe ) Queen Elizabeth Central Hospital Blantyre ( Malawi ) . These receive weekly treatment azithromycin placebo 12 month . Another 100 child ( 50 per site ) living HIV CLD enrol comparison group laboratory sub-studies . Lung function ass use spirometry Forced expiratory volume first minute ( FEV1 ) primary outcome . The mean change FEV1 z-score level compare trial arm 12 month initiation azithromycin treatment .</brief_summary>
	<brief_title>Bronchopulmonary Function Response Azithromycin Treatment Chronic Lung Disease HIV-infected Children</brief_title>
	<detailed_description>Clinical Phase : III Trial Design : Multi-site , individually randomise , double-blinded , placebo-controlled trial weekly azithromycin 12 month Trial Participants : Children age 6-16 year live HIV diagnosis chronic lung disease . Another 200 child live HIV chronic lung disease comparison arm . Planned Sample Size : 400 case 100 comparison arm Treatment duration : 12 month Follow duration : 18 month Planned Trial Period : June 2016-September 2019 Objectives : - Primary trial outcome : To investigate whether adjuvant treatment azithromycin result improvement lung function HIV-infected child chronic lung disease , stable antiretroviral therapy . - Secondary trial outcome : .To investigate intervention effect mortality , exacerbation lung disease , quality life morbidity.. .To investigate adverse event related azithromycin treatment . .-Laboratory sub-studies .To determine effect azithromycin therapy antimicrobial resistance bacteria colonize respiratory tract . .To investigate diversity composition respiratory microbiome HIV-infected child CLD . .To investigate diversity composition gut microbiome HIV-infected child CLD . .To investigate effect azithromycin biomarkers systemic inflammation HIV-infected child CLD . .-Cardiac sub-study : .Describe cardiac symptom echocardiograph finding HIV-infected child chronic lung disease . .To investigate whether adjuvant treatment azithromycin result improvement right-sided cardiac function and/or pulmonary hypertension HIV-infected child chronic lung disease . Investigational Medicinal Product ( ) : Azithromycin placebo . Formulation : Tablets 250 mg Dose : According weight band ( 30 mg/kg/week ) : - 10-20 kg : 250 mg - 20-29 kg : 500 mg - 30-39 kg : 750 mg - 40-49 kg : 1250 mg Route Administration : Oral</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<criteria>1 . Diagnosis chronic lung disease ( define FEV1 and/or FVC &lt; 80 % predict ) 2 . Age 616 year 3 . Perinatallyacquired HIV infection likely source transmission 4 . On first secondline ART least one year 5 . HIV1 viral load undetectable ( defined trial site ) 6 . A firm home address accessible visit intend remain 24 month 7 . Willing agree participate study give sample blood sputum 8 . HIV status disclose child age old 12 year 1 . Any condition ( except HIV ) may prove fatal study period ( e.g . malignancy , endstage HIV disease condition deem likely fatal trial physician ) 2 . Diagnosis active pulmonary TB 3 . Infection nontuberculous mycobacteria ( NTM ) 4 . Pregnant breastfeed 5 . Condition likely lead lack understand study procedure uncooperative behaviour e.g . neurocognitive disease , developmental delay psychiatric illness 6 . History prolong QTc syndrome current plan therapy drug likely cause cardiac dysrhythmias 7 . Abnormal ECG finding 8 . Acute respiratory tract infection enrolment ( patient eligible acute infection treat ) 9 . Creatinine clearance &lt; 30mls/minute 10 . ALT 2 time upper limit normal 11 . No defined guardian/stable caregiver 12 . No consent/assent guardian/child</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>